Viewing Study NCT00004498



Ignite Creation Date: 2024-05-05 @ 11:08 AM
Last Modification Date: 2024-10-26 @ 9:04 AM
Study NCT ID: NCT00004498
Status: TERMINATED
Last Update Posted: 2015-03-25
First Post: 1999-10-18

Brief Title: Phase I Study of Adenoviral Vector Mediated Gene Transfer for Ornithine Transcarbamylase in Adults With Partial Ornithine Transcarbamylase Deficiency
Sponsor: University of Pennsylvania
Organization: FDA Office of Orphan Products Development

Study Overview

Official Title: None
Status: TERMINATED
Status Verified Date: 2000-02
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: OBJECTIVES

I Determine the safety feasibility and potential efficacy of intravascular adenoviral vector mediated gene transfer in the liver in adults with partial ornithine transcarbamylase deficiency
Detailed Description: PROTOCOL OUTLINE This is a dose escalation study Patients undergo a femoral arterial placement of a hepatic intraarterial catheter Patients then receive adenoviral vector mediated gene transfer intravascularly over 30 minutes

Cohorts of 3 patients each receive escalating doses of adenoviral vector until the maximum tolerated dose is determined

Patients are followed at 3 5 7 8 15 and 29 days at 2 months and then every 3 months thereafter

Completion date provided represents the completion date of the grant per OOPD records

Study Oversight

Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
Secondary ID Type Domain Link
UPSM-FDR001529 None None None